Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.5992 USD -2.11% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Vaxart Inc?
Write Note

Vaxart Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vaxart Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Vaxart Inc
NASDAQ:VXRT
Total Equity
$68.4m
CAGR 3-Years
-31%
CAGR 5-Years
29%
CAGR 10-Years
-1%
Abbvie Inc
NYSE:ABBV
Total Equity
$6B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$18.4B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$15.6B
CAGR 3-Years
18%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$29.3B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
28%
No Stocks Found

Vaxart Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

VXRT Intrinsic Value
0.6663 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Vaxart Inc's Total Equity?
Total Equity
68.4m USD

Based on the financial report for Sep 30, 2024, Vaxart Inc's Total Equity amounts to 68.4m USD.

What is Vaxart Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-1%

Over the last year, the Total Equity growth was -4%. The average annual Total Equity growth rates for Vaxart Inc have been -31% over the past three years , 29% over the past five years , and -1% over the past ten years .

Back to Top